+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

The effect of the desglycinyl metabolite of remacemide hydrochloride (FPL 12495AA) and dizocilpine (MK-801) on endogenous amino acid release from mouse cortex



The effect of the desglycinyl metabolite of remacemide hydrochloride (FPL 12495AA) and dizocilpine (MK-801) on endogenous amino acid release from mouse cortex



British Journal of Pharmacology 116(8): 3087-3092



1. In this study the effect of FPL 12495AA, the desglycinyl metabolite of remacemide hydrochloride and dizocilpine (MK-801), on potassium- and veratridine-stimulated release of neurotransmitter amino acids from mouse cortical slices was investigated. 2. Veratridine (20 microM) and potassium (60 mM) produced a preferential release of glutamate and aspartate. Potassium-stimulated release was calcium-dependent, while veratridine-stimulated release was only partially affected by removal of calcium from the medium. 3. FPL 12495AA significantly inhibited veratridine- and potassium-stimulated release of glutamate and aspartate. Lower concentrations of FPL 12495AA were needed to inhibit veratridine-stimulated release of glutamate (12.5 microM) than potassium-stimulated release (100 microM). 4. Dizocilpine significantly inhibited veratridine- and potassium-stimulated release of glutamate and aspartate at concentrations of 100 microM and above. 5. FPL 12495AA and dizocilpine both have an affinity for the ion channel subsite of the N-methyl-D-aspartate (NMDA) receptor. The reduction of potassium-stimulated release of glutamate and aspartate by FPL 12495AA and dizocilpine is probably due to NMDA receptor blockade. 6. FPL 12495AA inhibited veratridine-stimulated release at a concentration of 12.5 microM while dizocilpine was effective only at a concentration of 100 microM. This difference in efficacy is probably due to the higher affinity of FPL 12495AA compared to dizocilpine at the veratridine-binding site on the sodium channel.

(PDF emailed within 0-6 h: $19.90)

Accession: 009567554

Download citation: RISBibTeXText

PMID: 8719781

DOI: 10.1111/j.1476-5381.1995.tb15109.x



Related references

The effect of the desglycinyl metabolite of remacemide hydrochloride and dizocilpine on endogenous amino acid release from mouse cortex. British Journal of Pharmacology 116(8): 3087-3092, 1995

Neurochemical actions of the desglycinyl metabolite of remacemide hydrochloride (ARL 12495AA) in mouse brain. British Journal of Pharmacology 121(5): 923-926, 1997

CSF concentrations of remacemide and its desglycinyl metabolite in a double blind placebo controlled study of 3 doses remacemide hydrochloride as add-on therapy in patients with refractory epilepsy. Epilepsia 37(SUPPL 5): 166, 1996

The desglycinyl metabolite of remacemide hydrochloride is neuroprotective in cultured rat cortical neurons. Journal of Neurochemistry 66(3): 989-995, 1996

Electrophysiological effects of the anticonvulsant remacemide hydrochloride and its metabolite ARL 12495AA on rat CA1 hippocampal neurons in vitro. Neuropharmacology. 36(7): 951-959, 1997

The effect of the desglycinyl metabolite of remacemide on cortical wedges prepared from DBA/2 mice. European Journal of Pharmacology 287(3): 251-256, 1995

Remacemide HCl and its metabolite, FPL 12495AA, limit action potential firing frequency and block NMDA responses of mouse spinal cord neurons in cell culture. Epilepsy Research 23(1): 1-14, 1996

Differential effects of remacemide and desglycinyl-remacemide on epileptiform burst firing in the rat hippocampal slice. Neuroscience Letters 321(1-2): 33-36, March 15, 2002

Na+ channel effects of remacemide and desglycinyl-remacemide in rat cortical synaptosomes. European Journal of Pharmacology 438(1-2): 63-68, 1 March, 2002

Pre-clinical studies with remacemide and desglycinyl remacemide. Epilepsia 41(Supplement 7): 36, 2000

The desglycine metabolite of remacemide inhibits the release of glutamate from mouse cortical slices. British Journal of Pharmacology 112(PROC SUPPL ): 630P, 1994

Binding of [3H]desglycinyl remacemide to rat brain membranes: association with the benzomorphan attachment site of the N-methyl-D-aspartic acid receptor channel. Brain Research 827(1-2): 46-50, 1999

Effect of phencyclidine on endogenous excitatory amino acid release from the rat anterior cingulate cortex--an in vivo microdialysis study. Journal of Neural Transmission. General Section 94(3): 235-240, 1993

Identification of a 3H-desglycinyl remacemide binding site in rat brain membranes. Society for Neuroscience Abstracts 22(1-3): 2105, 1996

The release of endogenous gamma amino butyric acid and glutamate from the cerebral cortex in the rat. Naunyn-Schmiedeberg's Archives of Pharmacology 316(3): 235-239, 1981